Therefore, the oncoprotein potential of HIF2α in ccRCC has led to the development of the HIF2α antagonists PT2399 and PT2385 to combat the progression of these tumors (23, 24). This evidence concerns the gene EPAS1 and nonpapillary renal cell carcinoma.